

Application No. 09/944,564 Page 1

Inventor: Nida Abdul-Ghani Nassief

CLAIMS

1 - 24. (Canceled)

*appealed*

25. (New) A pharmaceutical composition consisting essentially of glycoposphopeptical for oral administration for the treatment of allergy and asthma in dosage and duration which is effective to:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

26. *dependant* (New) A pharmaceutical composition of claim 25, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient.

27. *dependant* (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 25 for a short course of 1-14 days to induce a remission of 3-12 months.

28. *withdrawn* (New) A pharmaceutical composition for the treatment of allergy and asthma consisting essentially of the herbal seeds of *Nigella sativa* to act as a vaccine that is almost identical to Purified Protein Derivative from *Bacillus Calmette Guérin*:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

29. *withdrawn* (New) A pharmaceutical composition vaccine of claim 28, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient suffering from asthma and allergy.

30. *withdrawn* (New) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 28 for a short course of 1-14 days to induce a remission of 3-12 months.

31. *withdrawn* (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with Crohn's disease.

32. *withdrawn* (New) A method of treatment of Crohn's disease, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.

33. *withdrawn* (New) A pharmaceutical composition vaccine from *Nigella sativa*, to induce a clinical remission and long-term therapeutic effect in patients with influenza and common cold.

34. *withdrawn* (New) A method of treatment of influenza and common cold, comprising of administering the pharmaceutical composition vaccine from *Nigella sativa* for a short course of 1-14 days to induce symptomatic remission.

CLAIMS

- Cancelled*
1. Use of glycoposphopeptical for the treatment and/or prophylaxis of allergy/asthma for administration to a mammal such as a human in need of such treatment.

5

- Cancelled*
2. Use of glycoposphopeptical for the preparation of an asthma/allergy drug, such as extrinsic, intrinsic or mixed asthma, allergic and perennial rhinitis, allergic conjunctivitis, chronic urticaria, atopic dermatitis, and/or laryngeal oedema, to be administered to a mammal such as human in need of such treatment.

10

- Cancelled*
3. A Pharmaceutical composition comprises glycoposphopeptical, in any pharmacologically active form at a concentration of the extract which is effective as a Th1 stimulating agent.

- Cancelled*
4. A Pharmaceutical composition as claimed in claim 3 further comprising an excipient.

15

- Cancelled*
5. A method of treatment of diseases caused by type I IgE-mediated hypersensitivity reaction comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of glycoposphopeptical.

- Cancelled*
6. The claim 4 including a dosage regimen as a characterizing feature, administering to a patient suffering from a chronic disease a short-term therapy of 5-20 days, preferably 5 days, of a Th1 stimulating agent, to get a long-term clinical remission of months as a result of selective switching-off of the eosinophilic inflammation.

- Cancelled*
7. The use of the pure seeds of *Nigella sativa* for the preparation of an asthma and allergy agent in a concentration which was found to perform substantially the same function in substantially the same way to obtain substantially the same results as with glycoposphopeptical.

- Cancelled*
8. A Pharmaceutical composition as claimed in claim 6 further comprising an excipient.

- Cancelled*
9. A medicament as claimed in any preceding claim, which is adapted and/or packaged for

periodic administration to said mammal in doses over a period of 5-20 days, preferably 5 days in doses at least once daily up to ten times/day.

~~Cancelled~~

10. A medicament as claimed in claim 9, characterized in that each one of said doses comprises up to 2000mgs of said active agent, preferably about 200-1000mgs, of said active agent, adapted for oral administration to said mammal in capsules, or tablets, or lozenges, or as a powder, or a suspension, or a syrup

~~Cancelled~~

11. A medicament as claimed in any of claims 2, 3, and 7, which is adapted for topical administration to said mammal such as a human, in the form of eye or nasal drops or ointment, also skin or vaginal cream or ointment.

~~Cancelled~~

12. A kit comprising a medicament as claimed in claim 10 and 11 packaged in separate doses for periodic administration to said mammal such as a human, contains written or printed instructions.

15

~~Cancelled~~

13. The method of claim 5 and 7 is dependent on the fact that interferon is an in vivo Eosinophilic Chemotactic Factor, and that serum interferon and Th1 lymphocytes are controlling the pre-inflammatory phase of allergic reaction.

20

~~Cancelled~~

14. The manufacture of a diagnostic kit to diagnose allergy and asthma and to assess the severity Of the disease, using of a quantitative serum interferon concentration measurement.

~~Cancelled~~

15. The method of claim 5 and 7 wherein the recommended dose of Th1 lymphocytes stimulating agent is sufficient to selectively switch -off the eosinophilic inflammation in the patient's airway.

~~Cancelled~~

16. The method of claim 5 and 6 wherein Th1 lymphocytes stimulating agents, are capable of stimulating T lymphocytes in culture, comparable to Purified Protein Derivative of BCG, as a classical Cell Mediated Immunity stimulating agent.

~~Cancelled~~

17. Use of Th1 stimulating agents for the preparation of an agent for the treatment and/or prophylaxis of diseases characterized by a body immune defensive mechanism is Cell Mediated Immunity as viral respiratory tract infections such as, but not limited to influenza and common cold, other viral infections.

5

~~Cancelled~~

18. A method of treatment of viral respiratory tract infections such as, but not limited to influenza and common cold, other viral infections comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

10

~~Cancelled~~

19. Use of Th1 stimulating agents for the preparation of an agent for the treatment and/or prophylaxis of diseases characterized by a body immune defensive mechanism is Cell Mediated Immunity as acute and recurrent urinary tract infection, pelvic inflammatory diseases such as but not limited to neuroimmune appendicitis, and cancer.

15

~~Cancelled~~

20. A method of treatment of as acute and recurrent urinary tract infection, pelvic inflammatory diseases such as but not limited to neuroimmune appendicitis, and cancer comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

20

~~Cancelled~~

21. A method of treatment of crohns disease comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents in order to stimulate Cell Mediated Immunity.

~~Cancelled~~

22. Use of Th1 stimulating agent, for the treatment of crohns disease to be administered to a mammal such as a human in need of such treatment.

~~Cancelled~~

23. A method of treatment of facial palsy comprising the administration to a mammal such as a human in need of such treatment, of an effective dose of Th1 stimulating agents.

30

~~Cancelled~~

24. Use of Th1 stimulating agent, for the treatment of facial palsy to be administered to a mammal such as a human in need of such therapy.